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Abstract
Background: Mood disorders may affect lung cancer risk. We evaluated this hypothesis in two large studies.
Methodology/Principal Findings: We examined 1,939 lung cancer cases and 2,102 controls from the Environment And
Genetics in Lung cancer Etiology (EAGLE) case-control study conducted in Italy (2002–2005), and 82,945 inpatients with a
lung cancer diagnosis and 3,586,299 person-years without a lung cancer diagnosis in the U.S. Veterans Affairs Inpatient
Cohort (VA study), composed of veterans with a VA hospital admission (1969–1996). In EAGLE, we calculated odds ratios
(ORs) and 95% confidence intervals (CI), with extensive adjustment for tobacco smoking and multiple lifestyle factors. In the
VA study, we estimated lung cancer relative risks (RRs) and 95% CIs with time-dependent Poisson regression, adjusting for
attained age, calendar year, hospital visits, time within the study, and related previous medical diagnoses. In EAGLE, we
found decreased lung cancer risk in subjects with a personal history of mood disorders (OR: 0.59, 95% CI: 0.44–0.79, based
on 121 lung cancer incident cases and 192 controls) and family history of mood disorders (OR: 0.62, 95% CI: 0.50–0.77, based
on 223 lung cancer cases and 345 controls). The VA study analyses yielded similar results (RR: 0.74, 95% CI: 0.71–0.77, based
on 2,304 incident lung cancer cases and 177,267 non-cancer person-years) in men with discharge diagnoses for mood
disorders. History of mood disorders was associated with nicotine dependence, alcohol and substance use and
psychometric scales of depressive and anxiety symptoms in controls for these studies.
Conclusions/Significance: The consistent finding of a relationship between mood disorders and lung cancer risk across two
large studies calls for further research into the complex interplay of risk factors associated with these two widespread and
debilitating diseases. Although we adjusted for smoking effects in EAGLE, residual confounding of the results by smoking
cannot be ruled out.
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Introduction
Tobacco smoking, and other environmental and genetic factors
have all been implicated in lung cancer etiology [1]. Psychiatric
conditions have been hypothesized to have a relationship to lung
cancer risk, but the association is controversial [2,3].
Mood disorders, mainly unipolar and bipolar depression, are
the most common severe adult mental disorders and the most
important psychiatric causes of disability and morbidity worldwide
[4]. According to 2004 World Health Organization data, at any
one time, 151.2 and 29.5 million people may be suffering from
unipolar and bipolar depression, respectively [5].
Mood disorders, particularly depression, have been proposed as
risk factors for cancer through diverse mechanisms, including
effects on the immune system mediated through chronic stress,
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and associations with other risk factors such as smoking, poor diet,
and increased exposure to infectious agents [2]. Common
etiologies, genetic or pharmacological, have been proposed for
the consistent positive bidirectional associations between depres-
sion and smoking [6,7]. A common genetic predisposition to both
mood disorders and cancer has also been proposed [8].
Previous studies have investigated the relationship between
mood disorders and lung cancer incidence, with mixed results,
complicated by limited ability to control for potential confounders,
such as tobacco smoking and sample size. The majority have
found no significant associations. The diversity of study designs,
including assessment, diagnostic criteria, and detailed information
on risk factors makes comparison across studies challenging, and
sample sizes and corresponding person-years of follow up may
have limited power in some settings [9,10,11,12,13,14,15,16,17].
In order to examine the relations between mood disorders and
lung cancer, we investigated the association between them in two
large studies: the Environment And Genetics in Lung cancer
Etiology (EAGLE) study from the Lombardy region of Italy [18]
and the U.S. Veterans Affairs Inpatient Cohort Study (VA study),
including over 3.6 million adult White veteran men [19].
Unexpectedly, we found that lung cancer risk was inversely
associated with both family history of mood disorders in any first
degree-relative and personal history of mood disorders in the
EAGLE study, and with a discharge diagnosis for mood disorders
in the VA study.
Results
EAGLE Study
The analyses included 1,939 lung cancer cases and 2,102
controls. Sex, age and residence were not substantially different
between cases and controls since they were frequency matching
variables. Compared to controls, lung cancer cases tended to be
less educated, less likely to be married or cohabitating, and more
likely to be heavy drinkers and have higher smoking rates, e.g.,
higher intensity (packs per day) and longer duration (years) (Table
S1). Personal history of mood disorders requiring medication or
hospitalization was diagnosed in 121 (6.2%) lung cancer cases and
192 (9.1%) controls (92% provided information on their age or
year of mood disorder diagnosis) (Table 1). Women were almost
twice as likely to report mood disorders as men. Subjects with a
family history of mood disorders, cases with no education, current
smoker cases and never smoker controls were more likely to have a
personal history of mood disorders. Former smoker cases and
controls had a lower proportion of mood disorders. A personal
history of mood disorders was associated with increased smoking
duration (years) and fewer years since quitting smoking in both
cases and controls (Table 1). Overall, 223 (11.5%) cases, and 345
(16.4%) controls had a first-degree relative with a previous
diagnosis of mood disorders (Table 2). As expected, in control
subjects, personal or family history of mood disorders was
associated with depressive symptoms assessed by the Center for
Epidemiological Studies Depression Scale (CES-D) [20] and
Hospital Anxiety and Depression Scale (HADS) [21], and with
nicotine dependence as assessed by the Fagerstro¨m Test for
Nicotine Dependence (FTND) [22] (Table 3).
There was a significant inverse association of lung cancer with a
personal history of mood disorders (ORpersonal = 0.67, 95% CI:
0.53–0.85) or with a history of mood disorders in any first-degree
relative (ORfamily = 0.67, 95% CI: 0.56–0.81) (Table 4). These
associations strengthened after further adjustment for smoking-
related and alcohol consumption-related variables, education level
and marital status. Similar results were observed in subjects with a
family history of mood disorders in any first degree relative and in
individuals with a positive family history but no personal history of
mood disorders. Subjects with both a personal and a family history
of mood disorders showed the greatest reduction (ORboth = 0.51,
95% CI: 0.31–0.85). The estimates were essentially unchanged
after adjusting for smoking in any first degree relative or excluding
subjects (0.57% cases and 0.76% controls) who reported a personal
history of mood disorders but did not recall the date when they
began treatment or hospitalization (data not shown). The
Likelihood Ratio Test (LRT) showed a suggestive, but not
significant, interaction between smoking status (current, former
and never) and personal (P-value, LRT for interaction = 0.26) or
family (P-value, LRT for interaction= 0.11) history of mood
disorders (Table S2). No other interactions were identified
between the covariates in the adjusted model, history of mood
disorders and lung cancer risk.
The inverse associations with history of mood disorders were
greater in current (ORpersonal = 0.56; ORfamily = 0.53) and former
(ORpersonal = 0.48; ORfamily = 0.68) smokers than in never smokers
(ORpersonal = 0.97; ORfamily = 0.89), although homogeneity of ORs
was not formally rejected (Table S2). Similarly, the inverse
association was most pronounced in individuals who smoked .20
pack-years (Table S3). Sex did not modify the associations between
history of mood disorders and lung cancer (ORpersonal = 0.61;
ORfamily = 0.61, for males; ORpersonal = 0.58; ORfamily = 0.66 for
females; Table S4). Personal or family history of mood disorders
did not significantly differ by lung cancer histological type or
tumor grade (Table S5).
VA Study
Between 1969 and 1996, we identified 82,945 (2.3%) and
3,586,299 (97.7%) out of 3,669,244 white veterans with an
inpatient hospitalization for lung cancer and for conditions other
than lung cancer, respectively, at VA hospitals. The mean year of
entry was 1980 and the mean age of entry was 51.3 years.
Overall, 2,304 lung cancer cases and 177,267 non-cancer
patient person-years had a previous discharge diagnosis of any
mood disorders. Veterans hospitalized with mood disorders had a
significantly lower risk (RR: 0.74, 95% CI: 0.71–0.78) of lung
cancer, after adjustment for number of visits, age, calendar time
and latency, smoking related conditions (i.e., COPD, alcohol and
drug dependence and abuse and schizophrenia). The associations
were slightly stronger in subjects without smoking-related condi-
tions (Table 5). As expected, in veterans without lung cancer, the
frequency of alcohol dependence and abuse, substance depen-
dence and abuse, and schizophrenia was higher in subjects with
mood disorders (Table 5). No major differences were observed
when we stratified the analyses by year of hospitalization
discharge, although results were slightly stronger in the ICD-9
group, where adjustments benefitted from more stringent clinical
criteria (Table 6). Further adjustment for stroke and ischemic heart
disease did not modify the results (RR: 0.74, 95% CI: 0.71–0.77).
In addition, we examined other cancer types and did not observe a
consistent pattern of association, although mood disorders-related
protection was more frequent in smoking-related cancers (Table
S6).
As expected, lung cancer risk increased with age at study entry,
with numbers of hospital visits (which could be partially due to
subclinical lung cancer), COPD or alcohol abuse (Table S7). In
contrast, lung cancer risk decreased with the number of years of
follow-up and among those who had a date of first hospitalization
in the VA in the last period of follow-up (Table S7). We conducted
the same analyses also excluding subjects within the last categories
of Years of follow-up (15+ years) or Date of first hospitalization in
Mood Disorders and Lung Cancer Risk
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Table 1. Numbers and percentages of cases and controls with a personal history of mood disorders by demographic and
behavioral characteristics in the EAGLE Study, Italy, 2002–2005.
Characteristics Personal history of mood disorders
Lung cancer cases Controls
Yes (n =121) No (n=1,818) Yes (n=192) No (n =1,910)
n (%) n (%) n (%) n (%)
Sex
Males 77 (63.6) 1,455 (80.0) 113 (58.9) 1,493 (78.2)
Females 44 (36.4) 363 (20.0) 79 (41.2) 417 (21.8)
Age (years)
30–39 1 (0.8) 11 (0.6) 0 (0.0) 17 (0.9)
40–49 4 (3.3) 62 (3.4) 5 (2.6) 94 (4.9)
50–59 28 (23.1) 316 (17.4) 40 (20.8) 384 (20.1)
60–69 49 (40.5) 716 (39.4) 72 (37.5) 779 (40.8)
70–80 39 (32.2) 713 (39.2) 75 (39.1) 636 (33.3)
Residence
Brescia 17 (14.1) 230 (12.7) 18 (9.4) 229 (12.0)
Milano 86 (71.1) 1,189 (65.4) 135 (70.3) 1,290 (67.5)
Monza 7 (5.8) 125 (6.9) 8 (4.2) 109 (5.7)
Pavia 5 (4.1) 123 (6.8) 16 (8.3) 112 (5.9)
Varese 6 (5.0) 151 (8.3) 15 (7.8) 170 (8.9)
Any family history of mood disorders
Yes 34 (28.1) 189 (10.4) 66 (34.4) 279 (14.6)
No/Unknown 87 (71.9) 1,629 (89.6) 126 (65.6) 1,631 (85.4)
Cigarette status (lifetime)
Never 17 (14.1) 115 (6.3) 75 (39.1) 604 (31.6)
Former 38 (31.4) 800 (44.0) 69 (35.9) 833 (43.6)
Current 66 (54.6) 903 (49.7) 48 (25.0) 473 (24.8)
Cigarette intensity (packs/day)a 1.00 (0.75–1.35) 1.00 (0.75–1.50) 0.75 (0.48–1.00) 0.75 (0.48–1.00)
Cigarette duration (years)a 46.5 (36.5–52.5) 44.0 (36.0–51.0) 36.0 (23.0–45.0) 32.5 (21.0–44.0)
Years since quitting cigarettesa 7.5 (2.0–18.0) 10.0 (3.0–19.0) 18.0 (6.0–30.0) 20.0 (12.0–29.0)
Alcohol (grams)
0–4.9 g/day 31 (28.2) 327 (19.9) 52 (27.5) 423 (22.8)
5–14.9 g/day 13 (11.8) 239 (14.6) 38 (20.1) 367 (19.7)
15–29.9 g/day 27 (24.6) 409 (24.9) 44 (23.3) 462 (24.9)
30–59.9 g/day 32 (29.1) 491 (29.9) 40 (21.2) 532 (28.6)
.= 60 g/day 7 (6.4) 174 (10.6) 15 (7.9) 75 (4.0)
Education level
Non-educatedb 12 (10.0) 100 (5.5) 9 (4.7) 80 (4.2)
Elementary school 30 (25.0) 722 (39.7) 52 (27.1) 520 (27.2)
Middle/High School 71 (59.2) 903 (49.7) 115 (59.9) 1,066 (55.8)
University Degree 7 (5.8) 93 (5.1) 16 (8.3) 244 (12.8)
Marital status
Married or Cohabitating 86 (71.1) 1,407 (77.4) 142 (74.0) 1,595 (83.5)
Single/Separated/Widow/Divorced 35 (28.9) 411 (22.6) 50 (26.0) 315 (16.5)
Abbreviation: EAGLE, Environment And Genetics in Lung cancer Etiology.
aMedian (inter-quartile range).
b‘‘Non-educated’’ subjects are those who did not complete the elementary school.
Note: Numbers of participants may not sum to total due to missing data.
doi:10.1371/journal.pone.0042945.t001
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the VA (1990–1996) or both and found no substantial differences
from the full model (RR=0.70, 95%CI= 0.66–0.74; RR=0.75,
95%=0.71–0.80; RR=0.72, 95% CI= 0.68–0.77, respectively vs.
RR=0.74, 95%CI=0.71–0.78, full model).
Discussion
Using a case-control study from Lombardy in Italy, and a
nested-case control study from a cohort of US Veteran Affairs
Table 2. Numbers and percentages of cases and controls with a first-degree relative (mother, father, siblings, or children) with
history of mood disorders by demographic and behavioral characteristics in the EAGLE Study, Italy, 2002–2005.
Characteristics Family history of mood disorders
Lung cancer cases Controls
Yes No/Unknown Yes No/Unknown
(n=223) (n =1,716) (n =345) (n =1,757)
n (%) n (%) n (%) n (%)
Sex
Males 164 (73.5) 1,368 (79.7) 246 (71.3) 1,360 (77.4)
Females 59 (26.5) 348 (20.3) 99 (28.7) 397 (22.6)
Age (years)
30–39 0 (0.0) 12 (0.7) 2 (0.6) 15 (0.9)
40–49 8 (3.6) 58 (3.4) 20 (5.8) 79 (4.5)
50–59 52 (23.3) 292 (17.0) 74 (21.5) 350 (19.9)
60–69 85 (38.1) 680 (39.6) 142 (41.2) 709 (40.4)
70–80 78 (35.0) 674 (39.3) 107 (31.0) 604 (34.4)
Residence
Brescia 25 (11.2) 222 (12.9) 43 (12.5) 204 (11.6)
Milano 170 (76.2) 1,105 (64.4) 229 (66.4) 1,196 (68.1)
Monza 13 (5.8) 119 (6.9) 17 (4.9) 100 (5.7)
Pavia 11 (4.9) 117 (6.8) 25 (7.3) 103 (5.9)
Varese 4 (1.8) 153 (8.9) 31 (9.0) 154 (8.8)
Cigarette status (lifetime)
Never 18 (8.1) 114 (6.6) 100 (29.0) 579 (33.0)
Former 93 (41.7) 745 (43.4) 149 (43.2) 753 (42.9)
Current 112 (50.2) 857 (49.9) 96 (27.8) 425 (24.2)
Cigarette intensity (packs/day)a 1.00 (0.75–1.50) 1.00 (0.75–1.50) 0.75 (0.46–1.00) 0.75 (0.48–1.00)
Cigarette duration (years)a 44.0 (35.0–52.0) 45.0 (36.0–52.0) 32.0 (22.0–44.0) 33.0 (21.0–44.0)
Years since quitting cigarettesa 12.0 (3.0–20.0) 10.0 (3.0–18.0) 19.0 (8.0–28.0) 20.0 (12.0–30.0)
Alcohol (grams)
0–4.9 g/day 48 (23.9) 310 (20.0) 86 (25.5) 389 (22.7)
5–14.9 g/day 33 (16.4) 219 (14.1) 70 (20.8) 335 (19.6)
15–29.9 g/day 41 (20.4) 395 (25.5) 83 (24.6) 423 (24.7)
30–59.9 g/day 61 (30.4) 462 (29.8) 84 (24.9) 488 (28.5)
.= 60 g/day 18 (9.0) 163 (10.5) 14 (4.2) 76 (4.4)
Education level
Non-educatedb 13 (5.8) 99 (5.8) 8 (2.3) 81 (4.6)
Elementary school 72 (32.3) 680 (39.7) 87 (25.2) 485 (27.6)
Middle/High School 125 (56.1) 849 (49.5) 212 (61.5) 969 (55.2)
University Degree 13 (5.8) 87 (5.1) 38 (11.0) 222 (12.6)
Marital status
Married or Cohabitating 176 (78.9) 1,317 (76.8) 282 (81.7) 1,455 (82.8)
Single/Separated/Widow/Divorced 47 (21.1) 399 (23.3) 63 (18.3) 302 (17.2)
Abbreviation: EAGLE, Environment And Genetics in Lung cancer Etiology.
aMedian (inter-quartile range).
b‘‘Non-educated’’ subjects are those who did not complete the elementary school.
Note: Numbers of participants may not sum to total due to missing data.
doi:10.1371/journal.pone.0042945.t002
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hospital inpatients, we found a strongly reduced risk of lung cancer
in subjects with a personal history of mood disorders. Participants
with a family history of mood disorders also had a similar inverse
association with lung cancer risk, even in the absence of personal
mood disorders. The inverse association was stronger for subjects
who had both personal and family history of mood disorders.
Previous studies on the relationship between lung cancer and
mood disorders have been mixed. Most prospective investigations
examining this relationship, particularly major depression diagno-
sis, have not identified an association with lung cancer risk
[9,10,11,12,13,14,15,16], while one study [17], with 240 lung
cancer cases, found a positive association. These studies may have
been affected by the small sample size (only 3 studies [12,13,17]
included more than 65 cases with prior mood disorder diagnosis).
Moreover, most studies did not take into account potential
confounders, such as tobacco smoking or COPD [12,13,15,17],
allowed for concurrent diagnoses of mood disorders and lung
cancer [13] or used different ICD codes corresponding to broader
and possibly milder forms of mental disorders [12,17].
The relationship with both personal and family history of mood
disorders and lung cancer suggests that genetic, epigenetic factors
or shared environment could be plausible explanations. Indeed,
mood disorders have been associated with genetic effects [23],
environmental factors [4] or a combination of the two [24].
Treatment for mood disorders may have an effect on lung
cancer risk, possibly through the interaction between the use of
early generation antidepressants and the inhibition of pro-
inflammatory pathways [25] or cytochrome p450 enzymes known
to activate carcinogens in tobacco [26]. However, some studies
[27,28] reported that early antidepressant use is associated with
increased cancer risk, suggesting that the interplay between
smoking and medication, if any, is not straightforward. Also,
serotonin appears to stimulate the growth of certain lung cancers
[29,30,31,32,33]. Lowered serotonin levels in mood disorders have
been reported both in the central nervous system [34] and in the
periphery [35] with possible implications in lung cancer risk.
Mild depression may make individuals less prone to pursue
medical assistance [36], with resulting underestimation of mood
disorders. However, this should affect all subjects, regardless of
future lung cancer diagnosis. Resistance to seek medical care in
depressed people may also delay lung cancer diagnosis, but given
the inevitable progression and eventual hospitalization, recording
Table 3. Odds ratios (95% confidence intervals) of personal or family history of mood disorders among controls (n = 2,046) by
mood symptoms and measures of nicotine dependence, EAGLE Study, Italy, 2002–2005.
Behavioral characteristics Personal history of mood disorders
a Family history of mood disordersa
Yes No Adjusted model Yes
No/
Unknown Adjusted model
(n =189) (n =1857) (n =337) (n=1709)
n (%) n (%) OR (95% CI) n (%) n (%) OR (95% CI)
CES-D (symptoms during last week)b
,1 day 80 (42.3) 1399 (75.3) 1.00 219 (65.0) 1260 (73.7) 1.00
1–2 days 58 (30.7) 359 (19.3) 2.34 (1.60–3.44) 81 (24.0) 336 (19.7) 1.36 (1.02–1.83)
3–4 days 31 (16.4) 65 (3.5) 6.46 (3.79–11.02) 25 (7.4) 71 (4.2) 1.91 (1.17–3.11)
5–7 days 20 (10.6) 34 (1.8) 8.39 (4.23–16.65) 12 (3.6) 42 (2.5) 1.47 (0.75–2.90)
HADS – Depressionc
Normal 108 (57.5) 1352 (73.1) 1.00 223 (66.6) 1237 (72.6) 1.00
Borderline 51 (27.1) 365 (19.7) 1.61 (1.11–2.34) 83 (24.8) 333 (19.6) 1.37 (1.03–1.82)
Depressed 29 (15.4) 133 (7.2) 2.29 (1.41–3.73) 29 (8.7) 133 (7.8) 1.16 (0.75–1.78)
Missing Info 1 (0.5) 7 (0.4) NA 2 (0.6) 6 (0.4) NA
HADS – Anxiety
Normal 103 (54.5) 1444 (78.1) 1.00 232 (69.1) 1315 (77.3) 1.00
Borderline 38 (20.1) 294 (15.9) 1.54 (1.01–2.33) 61 (18.2) 271 (15.9) 1.23 (0.89–1.69)
Anxious 48 (25.4) 111 (6.0) 5.35 (3.44–8.30) 43 (12.8) 116 (6.8) 1.99 (1.35–2.93)
Missing Info 0 (0.0) 8 (0.4) NA 1 (0.3) 7 (0.4) NA
FTNDd
Light [,4 pts] 65 (34.4) 823 (44.3) 1.00 154 (45.7) 734 (43.0) 1.00
Moderate [4–6 pts] 31 (16.4) 322 (17.3) 1.49 (0.87–2.57) 61 (18.1) 292 (17.1) 1.00 (0.69–1.46)
Heavy [7–10 pts] 19 (10.1) 123 (6.6) 2.03 (0.98–4.23) 24 (7.1) 118 (6.9) 0.98 (0.56–1.72)
Never Smokers 74 (39.2) 589 (31.7) NA 98 (29.1) 565 (33.1) NA
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable; EAGLE, Environment And Genetics in Lung cancer Etiology.
aAdjusted ORs for sex, age, residence, education level, marital status, time-weighted mean alcohol consumption (grams/day), smoking status, years smoking regularly,
mean cigarettes per day, years since quitting cigarettes, and the interaction between MD and smoking status.
bCenter for Epidemiologic Studies – Depression.
cHospital Anxiety & Depression Scale.
dFagerstro¨m Test for Nicotine Dependence.
Note: Numbers of participants may not sum to total due to missing data.
doi:10.1371/journal.pone.0042945.t003
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of this aggressive disease is a virtual certainty. It can also be argued
that subjects with significant mood disorders may seek medical
attention on a more frequent basis. Surveillance bias, where lung
cancer diagnosis is identified more often in individuals previously
followed up due to mood disorder diagnosis would result in a
positive association and not inverse, as our study reports, although
more surveillance could also result in more frequent smoking
cessation counseling that might lessen future cancer rates.
Moreover, access to healthcare should not constitute a barrier to
identification of a diagnosis of mood disorders in either Italy
(which enjoys universal health care) or the US VA System
(generally free access for Veterans). While the VA study was based
on inpatient data potentially favoring more severe forms of mood
disorders, the EAGLE study should have also captured moderate
diagnoses treated on an outpatient basis. However, in Italy there is
a low propensity for individuals to reveal details of their personal
and emotional lives and only a small percentage of those suffering
from emotional or mental health problems consult a medical
professional [37]. Thus, the subjects with self-reported mood
disorders in EAGLE may reflect those with more severe diseases
similar to those requiring hospitalization as in the VA study.
A potential issue is that some emotional and cognitive signs of
mood disorders (e.g. weight loss, sleep perturbation and fatigue)
could derive from pre-clinical manifestations of lung cancer itself
[2]. We addressed this issue by excluding subjects with a discharge
record for any disease (in the VA study) or mood disorders (in
EAGLE) within a year from the cancer diagnosis.
Another concern is that people with mood disorders would
experience increased mortality due to comorbid conditions such as
cardiovascular disease or suicide [4,38], and this would be
reflected in an inverse association with cancer. However, further
adjustment for stroke and ischemic heart disease did not modify
the results, suggesting competing mortality from these sources
cannot account for the observation.
Our research had several important strengths: although not fully
comparable, both studies represented large populations with
standardized access to medical care and different epidemiological
designs. The VA cohort study featured extended follow-up among
males and data on multiple medical conditions while the EAGLE
case-control study considered both personal and family history of
mood disorders, as well as psychometric scores for mood disorder
symptoms. In addition, while one study design was based on self-
reported questionnaire data, the other was based on medical
records; both resulted in similar findings with high statistical
significance. However, the results may only be generalizable to
men, as women were not included in the VA cohort study analysis
and were less commonly represented in the EAGLE case-control
study.
Although we present the largest effort to date to evaluate the
association between a previous history of mood disorders and risk
of incident lung cancer, our work has several limitations.
Misclassification or under-reporting of personal or family history
of mood disorders, particularly in EAGLE, where severe
depression requiring medication or hospitalization was the
inclusion criterion, cannot be completely excluded. However,
any such misclassification or under-reporting would probably be
nondifferential.
The self-reported mood disorders in EAGLE may be subject to
recall bias. However, the self-reported history of mood disorders
among controls (91.7% of whom recalled their date of diagnosis or
inpatient mood disorders care) was strongly (P,0.0001, Wald test)
positively correlated with the CES-D and HADS scores, suggest-
ing that a self-reported history of mood disorders does reflect a
past mood disorder diagnosis. Moreover, the prevalence of mood
disorders among EAGLE controls in the Lombardy region (9.1%
overall, and 7.0% and 15.9% among males and females,
respectively) is very similar to the lifetime prevalence of any mood
disorders in Italy’s non-institutionalized adult population during
1998 (11.2% overall, and 7.2% and 14.9% among males and
Table 4. Numbers and percentages of cases and controls, and risk estimates for lung cancer by categories of personal or family
history in the EAGLE Study, Italy, 2002–2005.
History of mood disorders
Mood disorders status Lung cancer cases Controls Minimally adjusted
a Fully adjustedb
(n =1,939) (n =2,102)
Yes No Yes No
n (%) n (%) n (%) n (%) OR (95% CI) OR (95% CI)
Personal history 121 (6.2) 1,818 (93.8) 192 (9.1) 1,910 (90.9) 0.67 (0.53–0.85) 0.59 (0.44–0.79)
Any first degree relative history 223 (11.5) 1,716 (88.5) 345 (16.4) 1,757 (83.6) 0.67 (0.56–0.81) 0.62 (0.50–0.77)
Personal with no/unknown family history 87 (4.5) 1,852 (95.5) 126 (6.0) 1,976 (94.0) 0.75 (0.56–0.99) 0.65 (0.46–0.92)
Family with no personal history 189 (9.8) 1,750 (90.3) 279 (13.3) 1,823 (86.7) 0.72 (0.59–0.87) 0.67 (0.53–0.85)
Both personal & family history 34 (1.8) 1,905 (98.3) 66 (3.1) 2,036 (96.9) 0.57 (0.37–0.86) 0.51 (0.31–0.85)
Mother with history 61 (3.3) 1,787 (96.7) 112 (5.5) 1,911 (94.5) 0.61 (0.44–0.84) 0.66 (0.45–0.96)
Father with history 24 (1.3) 1,792 (98.7) 50 (2.5) 1,934 (97.5) 0.55 (0.33–0.89) 0.58 (0.32–1.06)
Any sibling’s history 104 (6.3) 1,556 (93.7) 167 (9.4) 1,611 (90.6) 0.65 (0.50–0.84) 0.59 (0.43–0.81)
Any children’ history 59 (3.6) 1,575 (96.4) 91 (5.1) 1,706 (94.9) 0.70 (0.50–0.98) 0.57 (0.38–0.86)
Abbreviations: OR, odds ratio; CI, confidence interval; EAGLE, Environment And Genetics in Lung cancer Etiology.
aAdjusted for sex, age and residence.
bAdjusted for sex, age, residence, smoking status, years smoking regularly, mean cigarettes per day, years since quitting cigarettes, time weighted mean alcohol
consumption (grams/day), education level and marital status.
Note: Numbers of participants may not sum to total due to missing data.
doi:10.1371/journal.pone.0042945.t004
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Table 5. Relative risks and 95% confidence intervals for lung cancer overall and by other medical conditions in the United States
Veterans Affairs Inpatient Cohort: White males (n = 3,669,224) with at least one hospital admission between July 1, 1969 and
September 30, 1996.
History of Mood Disordersa
Lung cancer patients Non-cancer patients
Medical conditions (number) (person-years) Adjusted model
b
Yes No Yes No
n (%)c n (%)c RR (95% CI)
Overall 2,304 (100) 80,641 (100) 177,267 3,409,032 0.74 (0.71–0.78)
COPDd
Yes 1,070 (46.4) 28,148 (34.9) 37,577 576,941 0.82 (0.77–0.88)
No 1,234 (53.6) 52,493 (65.1) 139,690 2,832,091 0.68 (0.64–0.71)
Alcohol dependence and abusee
Yes 1,176 (51.0) 23,413 (29.0) 88,048 812,786 0.79 (0.75–0.84)
No 1,128 (49.0) 57,228 (71.0) 89,219 2,596,246 0.67 (0.63–0.71)
Substance dependence and abusef
Yes 206 (8.9) 1,000 (1.2) 44,537 170,754 0.84 (0.72–0.97)
No 2,098 (91.1) 79,641 (98.8) 132,730 3,238,278 0.72 (0.68–0.75)
Schizophreniag
Yes 674 (29.3) 3,881 (4.8) 47,914 168,820 0.77 (0.71–0.84)
No 1,630 (70.8) 76,760 (95.2) 129,353 3,240,212 0.71 (0.67–0.74)
Abbreviations: RR, relative risk; CI, confidence interval; COPD, Chronic Obstructive Pulmonary Disease; ICD, International Classification of Disease.
aICD-8 & ICD-9, code 296 which includes depression and bipolar I disease.
bAdjusted for number of visits, age, latency, calendar time, and by the stratifying variables (COPD, alcohol and substance dependence and abuse, and schizophrenia)
when appropriate.
cPercentage of participants with mood disorders within each medical condition.
dICD-8 & ICD-9, codes 490–492.
eICD-8 & ICD-9, codes 291, 303, 305.0, 535.3, 571.0–571.3, 980.0.
fICD-8 & ICD-9, codes 304–305.
gICD-8 & ICD-9, code 295.
Note: Numbers of participants may not sum to total due to missing data.
doi:10.1371/journal.pone.0042945.t005
Table 6. Relative risks and 95% confidence intervals for lung cancer overall and by period of discharge from the United States
Veterans Affairs Inpatient Cohort: White males with at least one hospital admission between July 1, 1969, and September 30, 1996.
Model Lung cancer cases with mood disorders
a
ICD-8 ICD-9 All
[1969–1979] [1980–1996]
(n =1,617) (n=687) (N=2,304)
RR (95% CI) RR (95% CI) RR (95% CI)
Model adjusted for number of visits, attained age, calendar time and latency (Basic Model) 0.76 (0.73–0.81) 0.69 (0.63–0.74) 0.74 (0.71–0.77)
Basic model further adjusted for alcoholb and drugc dependence and abuse 0.75 (0.71–0.79) 0.67 (0.62–0.72) 0.72 (0.69–0.75)
Basic model further adjusted for alcoholb and drugc dependence and abuse, COPDd and
schizophreniae
0.77 (0.73–0.81) 0.70 (0.64–0.76) 0.74 (0.71–0.78)
Abbreviations: RR, relative risk; CI, confidence interval; COPD, Chronic Obstructive Pulmonary Disease; ICD, International Classification of Disease.
aICD-8 & ICD-9, code 296; which includes depression and bipolar disease.
bICD-8 & ICD-9, codes 291, 303, 305.0, 535.3, 571.0–571.3, 980.0.
cICD-8 & ICD-9, codes 304–305.
dICD-8 & ICD-9, codes 490–492.
eICD-8 & ICD-9, code 295.
Note: Numbers of participants may not sum to total due to missing data.
doi:10.1371/journal.pone.0042945.t006
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females, respectively) [37]. Finally, the VA study was based on
discharge records, with no risk of recall bias.
Smoking could be an important confounder and/or effect
modifier of mood disorders-lung cancer risk associations [39]. Our
results show a suggestive, but not significant, interaction between a
personal history of mood disorders and smoking status in EAGLE.
In fact, the negative association between mood disorders and lung
cancer risk was evident in current and former smokers, but not in
never smokers, although this last category included only a small
number of cases. Similarly, in the analyses of other cancers in the
VA study, we found that mood disorders-related protection was
more frequent in smoking-related cancers than in those less
strongly associated with tobacco smoking (Table S6). However, in
the VA study, subjects without smoking-related conditions showed
a stronger risk reduction, although we cannot exclude that some
smokers were included in this group. Moreover, in the VA study,
medical conditions used as surrogate variables for smoking habits
or alcohol consumption likely underestimate the actual presence of
these exposures. Nonetheless, if these factors were decisive
confounders then statistical adjustment for these surrogate
variables should decrease the resultant effect estimates, but no
major changes were observed. In the EAGLE study we were able
to use individual smoking data to directly take into account
smoking, and the strength of the inverse association was increased
upon adjustment for detailed smoking and alcohol data. Finally,
we cannot exclude that cigarette smoking could be used as ‘‘self-
medication’’ for mood disorders and in this case, the ‘‘non-mood
disorders’’ group used as reference for the association might
include some milder forms of mood disorders ‘‘treated’’ by
smoking. Since smoking is a strong risk factor for lung cancer and
residual confounding from smoking can never be ruled out, follow-
up in subjects with other smoking related conditions and in larger
samples of non-smoking lung cancer patients is warranted.
In conclusion, using data from two different populations and
study designs, we found an inverse association between lung
cancer risk and personal or family history of mood disorders. This
replicated finding could suggest a new insight in the development
of these two widespread and debilitating diseases, although the
association could have been affected by tobacco smoking. Further
large-scale laboratory and human population and behavior
research is necessary to clarify the complex interplay among
smoking behavior, inherited susceptibility, mood disorders and
cancer risk.
Materials and Methods
Ethics Statement
The Environment And Genetics in Lung cancer Etiology
(EAGLE) study was approved by the Institutional Review Board
(IRB) of each participating hospital and The University of Milan
in Italy and by the National Cancer Institute, NIH, in Bethesda,
MD. All subjects provided written consent. A detailed description
and link to the respective hospitals is available on the EAGLE
website (http://dceg.cancer.gov/eagle). Since no personal identi-
fiers were associated with the Veterans Affairs study existing
database, and we had no contact with the subjects, the National
Institutes of Health (NIH) Office of Human Subjects Research
granted us exemption from the Institutional Review and an
informed consent waiver.
Study populations
EAGLE study (http://eagle.cancer.gov). The EAGLE
study design and related investigations have been previously
described [18]. Briefly, EAGLE enrolled 2,100 incident primary
lung cancer cases and 2,120 population-based healthy controls,
35–79 years old, in Italy’s Lombardy region, between April 2002
and June 2005. Lung cancer diagnoses were confirmed histopath-
ologically in 95% of cases and by imaging and clinical charts in the
remaining 5%. Controls were randomly selected from the
Lombardy Regional Health Service population database and
frequency matched to cases by age (5-year classes), sex and area of
residence. The response rate was 86.6% and 72.4% for eligible
cases and controls, respectively.
VA study. Patients from the VA Department were selected
from computerized discharge records for inpatient visits from the
Patient Treatment File from July 1, 1969 to September 30, 1996 at
142 US VA hospitals. These subjects derived from approximately
30 million US veterans eligible for admission to VA hospitals
during the study period [40]. To reduce the risk of reverse
causality, follow-up began one year after the date of the first
hospital discharge for any condition and continued until the end of
the observation period, diagnosis of any cancer, or death,
whichever occurred first. Dates of death were identified by record
linkage to the Social Security Administration Death Master Files
[41] by the US Department of VA, prior to granting the
investigators access to the data. Our study included 3,669,244
white males, age 18 or older without a prior diagnosis of
malignancy if they were hospitalized at least once during the
study period, were cancer free during the first year of follow-up
and survived at least 1 year after the initial visit. Women and non-
whites (due to small numbers), non-veterans and those with
documented cancer or death during the first year of follow-up
were excluded.
Exposure ascertainment
EAGLE study. In EAGLE, we ascertained a personal history
of mood disorders by asking: ‘‘Have you ever been told by a doctor
that you had severe depression requiring medication or hospital-
ization?’’ and ‘‘How old were you or in what year was this
condition first diagnosed?’’. We cannot rule out that EAGLE’s
participants with depression had or developed a broader mood
disorder diagnosis. For example, a diagnostic change from
depression to bipolar illness of about 1% per year is expected
[42]. Thus, for consistency, we defined depression as ‘‘mood
disorders’’ throughout the paper.
A family history of mood disorders was ascertained from the
study subjects for each first-degree relative (mother, father,
siblings, and children) with the same two questions. The number
of siblings in the families ranged from 0 to 18, with a mode of 3
and with 10% with 7 or more siblings. As there were only 16 cases
and 17 controls reporting more than one sibling with mood
disorders, we defined the family history in siblings, ‘‘yes’’ as having
any affected sibling in the family. Similarly, the number of children
in the families ranged from 0 to 10, with a mode of 2 and with 7%
with 4 or more children. We defined the family history in children
as we defined family history in siblings. Families who had any
relative with mood disorder diagnosis were defined as ‘‘yes’’.
Subjects with missing information for these questions were
assigned to ‘‘no’’. In a sensitivity analysis we excluded all cases
(28.7%) and controls (26.1%) with missing information on family
history of mood disorders and observed very similar results.
Reported results are based on the entire sample.
The questionnaire provided demographic characteristics (i.e.,
sex, educational level, marital status), detailed personal smoking
history (e.g., number of cigarettes/day, age at initiation, duration,
passive smoking and quitting history), and smoking habits of first-
degree relatives. Smoking status was categorized as never (smoked
less than 100 cigarettes during lifetime), former (quit smoking at
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least six months or more before interview), and current smokers
(still smoking or quit less than six months before interview). We
computed the average consumption of alcohol in grams/day and
obtained a score for the FTND [22]. Personal symptoms of
depression and anxiety more than a year prior to enrollment were
evaluated through psychometric measures, i.e., the CES-D [20]
and the HADS [21].
We excluded 179 (4.3%) EAGLE participants who did not
respond to questions related to personal history of mood disorders,
and one case with a date of mood disorder diagnosis less than one
year before enrollment in the study. The proportion of excluded
cases (n = 161, 7.6%) and controls (n = 18, 0.8%) mirrored non-
response rates in the whole questionnaire (7.4% and 0.2%, for
cases and controls, respectively). The distribution of the major risk
factors for lung cancer (i.e., smoking status, cigarette pack-years,
alcohol consumption, age, sex, educational level, and marital
status) did not significantly differ between nonresponders and
responders to the depression/anxiety psychometric scores. There
was no evidence of heterogeneity by case status based on the
ability to recall the diagnosis’ date of mood disorders (P=0.83,
Wald test).
VA study. In the VA study, we assessed cancer incidence,
personal history of mood disorders and related medical conditions
based on the ICD8-Adapted (ICD8-A, from 1969 to 1979) and
ICD9-Clinical Modification (ICD9-CM, from 1980 to 1996) [43]
revisions. The description of the conditions is reported in Table
S8.
Statistical analyses
EAGLE study. Odds ratios (ORs) and 95% confidence
intervals (CIs) were estimated using unconditional logistic regres-
sion adjusted for age, sex, residence, weighted average grams per
day of alcohol consumption, educational level, marital status and
smoking. Smoking adjustment included smoking status (catego-
rized as never [smoking,100 cigarettes in a lifetime], former [quit
smoking $6 months before interview], or current), smoking
duration, cigarettes per day, years since quitting (in former
smokers), and exposure to environmental tobacco smoke (during
childhood, adulthood and at work, in never smokers only). Further
adjustment for family history of smoking, body mass index, and
history of asthma did not alter estimates, so they were not included
in the final model. Interactions between covariates in the adjusted
model, history of mood disorders and lung cancer risk were
evaluated using the LRT. Stratified analyses were performed by
smoking status (current, former, and never smokers) and sex.
Homogeneity among histologic and grade specific lung cancer
risks was evaluated using the Wald test. We used SAS software,
version 9.1 (SAS Institute Inc., Cary, North Carolina).
VA study. Relative risks (RR) and 95% CIs for lung cancer
incidence in the VA study sample were calculated with Poisson
regression [44], using Epicure AMFIT 2.0 (HiroSoft International
Corp, Seattle, Washington). Person-years were stratified by
categories of attained age (,40, 40–49, 50–59, 60–69, 70–79,
$80 years), calendar-year (1969–1974, 1975–1979, 1980–1984,
1985–1989, 1990–1996), hospital visits during the follow up period
(1–2, 3–4, $5 visits), time between study entry and exit (2–3, 4–5,
6–9, 10–14,$15 years), occurrence (yes/no) of chronic obstructive
pulmonary disease (COPD), drug dependence and abuse, alcohol-
related diagnoses, and schizophrenia. All variables, except number
of hospital visits, were treated as time-dependent. To account for
potential changes in variable definitions from ICD8-A (1969–
1979) to ICD9-CM (1980–1996) periods, we stratified the results
by these two calendar periods. Hospital admission date was used as
the cancer diagnosis date, and hospital discharge date was used for
all other diagnoses.
No direct measurements of smoking or alcohol consumption
were available. As surrogates, we used ICD8-A and ICD9-CM
diagnostic codes for COPD and drug dependence and abuse, as
well as alcohol related diagnoses, respectively. Further adjustment
for schizophrenic disorders, often associated with mood disorders,
and for ischemic heart disease and stroke was also performed.
Table S8 presents the ICD8-A and ICD9-CM discharge codes
used to define the relevant covariates.
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